Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 625-630

  Horiguchi, Jun ^a   Rai, Yoshiaki ^b   Tamura, Kazuo ^c   Taki, Toshihiko ^d   Hisamatsu, Kazufumi ^e   Ito, Yoshinori ^f   Seriu, Taku ^g   Tajima, Tomoo ^h  

^a GUNMA UNIVERSITY HOSPITAL   (Japan)

^b SAGARA HOSPITAL   (Japan)

^c FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^d Kitano Hospital   (Japan)

^e HIROSHIMA CITY ASA HOSPITAL   (Japan)

^f Cancer Institute Hospital   (Japan)

^g BRISTOL MYERS SQUIBB   (United States)

^h TOKAI UNIVERSITY TOKYO HOSPITAL   (Japan)

Author keywords

Metastatic breast cancer; Phase II study; Weekly paclitaxel

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BREAST CANCER; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; FLUSHING; GASTRITIS; GASTROENTERITIS; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPESTHESIA; HYPOALBUMINEMIA; HYPOTENSION; HYPOXIA; INTERSTITIAL LUNG DISEASE; JAPAN; JAPANESE; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PATHOLOGIC FRACTURE; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SALMONELLOSIS; SEPSIS; SIDE EFFECT; SUDDEN DEATH; TASTE DISORDER; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 61449085787     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Löffler TM: Is there a place for "dose-dense" weekly schedules of the taxoids? Semin Oncol 25(Suppl): 32-34, 1998.
2. Fennelly D, Aghajanian C, Shapiro F et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15: 187-192, 1997.
3. Choy H, Safran H, Akerley W et al: Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4: 1931-1936, 1998.
4. Seidman AD, Hudis CA, Albanell J et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353-3361, 1998.
5. Perez EA, Vogel CL, Irwin DH et al: Weekly paclitaxel in women aged 65 and above with metastatic breast cancer. Breast Cancer Res Treat 73: 85-88, 2002.
6. Gori S, Mosconi AM, Basurto C et al: Weekly paclitaxel in metastatic breast cancer patients: a phase II study. Tumori 88: 470-473, 2002.
7. Lombardi D, Crivellari D, Scuderi C et al: Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: A phase II monoinstitutional study. Tumori 90: 285-288, 2004.
8. Wist EA, Sommer HH, Østenstad B et al: Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol 43: 11-14, 2004.
9. Kim R, Osaki A and Toge T: Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer. Oncol Rep 10: 145-150, 2003.
10. Sato K, Inoue K, Saito T et al: Multicenter phase II trial of weekly paclitaxel for advanced or metastatic breast cancer: the Saitama Breast Cancer Clinical Study Group (SBCCSG-01). Jpn J Clin Oncol 33: 371-376, 2003.
11. ten Tije AJ, Smorenburg CH, Seynaeve C et al: Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 40: 352-357, 2004.
12. Taguchi T, Aihara T, Takatsuka Y et al: Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J 10: 509-513, 2004.
13. Nishimura R, Ogawa T, Kato M et al: Weekly paclitaxel in the treatment of advanced or metastatic breast cancer previously treated or not treated with docetaxel: a phase II study. Chemotherapy 51: 126-131, 2005.
14. Nokihara H, Tamura T, Matsumoto Y et al: Weekly paclitaxel in solid tumor, a phase I trial. Jpn J Lung Cancer, 43rd annual meeting abstracts. 42: 395, 2002 (in Japanese).
15. Ito Y, Horikoshi N, Watanabe T et al: Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. Invest New Drugs 16: 183-190, 1998.
16. Rai Y, Tajima T, Tamura K et al: Weekly paclitaxel in patients with metastatic or advanced breast cancer. Joint Meeting of the 3rd ISC International Conference on Cancer Therapeutics and 11th International Symposium on Cancer Chemotherapy abstracts, Tokyo, December pp. 6-8, 2006.
17. Winer EP, Berry DA, Woolf S et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22: 2061-2068, 2004
18. Seidman AD, Berry D, Cirrincione C et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of cancer and leukemia Group B Protocol 9840. J Clin Oncol 26: 1642-1649, 2008.
19. Akerly W, Sikov WM, Cummings F et al: Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: A preliminary report. Semin Oncol 24(suppl): 87-90, 1997.